CSL - UBS rates the stock as Buy
Get More Commentary, Discussion & Market Information On -
UBS observes weakness in a competitor has again delivered upside to CSL. Sales of the company's Haegarda for hereditary angioedema have been materially boosted in the US and EU because of another shortage of a rival's product, which has persisted since June.
CSL has advised patient groups that Haegarda production is not able to supply the gap left in the market. UBS suspects outperformance relative to FY18 net profit guidance and its forecasts is capped by the company's ability to respond to the additional demand.
Buy and $141.00 target maintained.
Sector: Pharmaceuticals & Biotechnology.
Target price is $141.00.Current Price is $136.58. Difference: $4.42 - (brackets indicate current price is over target). If CSL meets the UBS target it will return approximately 3% (excluding dividends, fees and charges - negative figures indicate an expected loss).
FN Arena is building the future of financial news reporting at www.fnarena.com. Our daily news reports can be trialed at no cost and with no obligations. Simply sign up & get a feel for what we are trying to achieve.
The content of this information does in no way reflect the opinions of FN Arena, or of its journalists. In fact we don't have any opinion about the stock market, its value, future direction or individual shares. FN Arena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface. This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FN Arena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.